Say Hello to Our New Logo
22 February 2023
Did you know that Molzym turns 20 this year?
So it's the perfect time for us to unveil a new little something... Our beloved logo has been given a makeover for this occasion! Same name (of course), same colors (yes), but definitely something more modern, innovative and forward-looking that embodies our vision. Do you like it?
Our new graphic identity will be supported by a set of brand new materials that we will reveal to you in the coming weeks.
Stay tuned!
Molzym is Pleased to Announce its Partnership with the French Society of Microbiology (SFM)
13 December 2022
Molzym and SFM share the same desire to promote and stimulate the field of microbiology. More than ever, we want to create synergies with experts who are at the heart of our research, to develop innovative and clinically relevant solutions for the microbiology and infectious disease actors.
SFM is a scientific association of health professionals aiming to promote and develop fundamental and applied research related to the field of microbiology.
www.sfm-microbiologie.org
On-Demand Webinar "Unleash the Power of mNGS to Identify Infectious Agents in Complex Human Samples"
14 September 2022
A major challenge to enhance the use of mNGS for the identification of infectious agents is linked to the vast excess of human DNA, which negatively impacts sequencing results, sensitivity and the overall workflow. In this webinar, Marina Linow shows how human DNA depletion by MolYsis™ can help overcome such limitations, improve sequencing depth and quality, and reduce the time and costs of analysis.
Link to the webinar (after registration you can directly enter the auditorium to watch the webinar)
The MolYsis™ technology is the basis for various kits and sample materials as outlined in this product brochure.
Molzym Announces Double-Digit Million EUR Capital Increase
29 June 2022
Today we have exciting news to share: We are very proud to announce a double-digit million EUR investment by a large single family office.
The capital will be deployed for our international business expansion, in particular for market entry and expansion in the US and China as well as further expansion of our presence in Europe. Furthermore, we want to announce our new Supervisory Board with Veronika Clarici-Fanfule as the new Chairwoman. We also welcome Dr. Kerstin Waterloh, Dr. Georg Lautscham, Dr. Gerhard Ries and Vladimir Soha to the board, who all have solid experience in the MedTech and Diagnostics market.
Please follow the link for the official press release!
Molzym announces FDA Breakthrough Device Designation for its Molecular Diagnostic Test System – Sepsis, Joint & Implant infections, Infective Endocarditis, Bacterial Meningitis
10 May 2021
Molzym’ s unique technology for molecular microbial diagnostics was granted Breakthrough Device Designation (BDD) by the FDA in light of its capacity to aid the diagnosis of selected conditions as an adjunct to the current standard of care.
The FDA BDD Program aims at providing patients and health care providers with timely access to these breakthrough medical devices and enhances Molzym’s marketing strategy. Read more in our press release.
Molzym GmbH & Co. KG and Fraunhofer IZI-BB Joint Research and Development Project
02 December 2020
In our latest press release we are delighted to present our new funding project: in collaboration with Fraunhofer IZI-BB, we develop an automated sepsis diagnostic for fast testing in clinical laboratories. The project is funded by the European Regional Development Fund (ERDF) and the federal state of Brandenburg (ILB)
The new analytical platform, called AutoSepT, which will identify the most frequent sepsis-causing pathogens.
Read more about the project including a statement of the project leader, Dr. Michael Lustig, in our press release.
Webinar Recording „Management of Bacterial and Fungal Infections: Efficiency of Culture-Independent Molecular Testing”
25 November 2020
Dr. Michael Lustig, Molzym’s COO, shares in this webinar his vast experience in direct molecular testing beginning with the limitations of conventional cultures and the culture-independent approaches available.
Get an overview of available solutions, their advantages and disadvantages. Get to know the aspects that favour direct molecular testing and learn about the diagnostic value and clinical impact of broad-range 16S & 18S rRNA analyses.
Please find the product information for our diagnostic solutions here and do not hesitate to contact us if you have any questions.
Diese E-Mail-Adresse ist vor Spambots geschützt! Zur Anzeige muss JavaScript eingeschaltet sein!
Webinar Recording “Direct Molecular Testing of Infectious Pathogens”
14 September 2020
How can molecular diagnostics be used for the identification of pathogens and resistance genes? What to consider with the different molecular diagnostic methods at hand and how to evaluate the results?
Request the recording of the live-webinar about “Direct molecular testing of infectious pathogens” by Prof. Dr. med. Sören Schubert from the Ludwig-Maximilian-University (LMU) Munich and learn about molecular diagnostics and his tips for clinical practice.
One of the methods presented is our Micro-Dx™ kit and we are very happy to answer any questions on the kit or technology.
Diese E-Mail-Adresse ist vor Spambots geschützt! Zur Anzeige muss JavaScript eingeschaltet sein!
Molzym Announces New Board of Directors to Accelerate Growth of its Molecular Diagnostic Solutions
09 July 2020
Molzym’s team is ready to expand its unique microbial molecular diagnostic solutions for tomorrows’ Healthcare systems, and glad to announce a new Board of Directors has joined to accelerate its growth. We are happy to share with you the latest press release with statements from our new Chairman, Jakob Glatz, and the CEO of Gradian and Molzym, Gabriel Tirouflet.
Molzym Operational Status - Statement to COVID-19
23 March 2020
As COVID-19 continues to impact the globe we want to address how Molzym is dealing with the current situation.
Operational Status
We are fully operational and have not experienced any impact on resources and logistics yet and process orders as usual. For the safety of our customers and employees, Molzym is taking any precautions to prevent the spread of COVID-19. Therefore, we have implemented strict travel restrictions and whenever possible our staff is working from home office.
Manufacturing & Shipping
We have implemented a shift-based system for production, assembly, processing and shipment of orders. Two teams plus backup staff are working without having direct contact to each other to ensure the supply of your products as you are used to. We are permanently monitoring our supply chain and are in close contact to our suppliers and freight forwarders to understand and identify any risks in supplies and shipments as early as possible. If there are any delays in production or delivery we will notify you immediately.
Customer Service & Technical Support
Our Customer service and technical support is available during regular business hours to help you with your needs and to answer your questions on the phone or via e-mail.
We will continue to monitor the COVID-19 situation and will update our operational status if needed.
Please follow the link for the pdf version of this statement.
Molzym is Now Part of Gradian Diagnostics!
16 December 2019
We are very pleased to inform you that Molzym GmbH & Co. KG has joined Gradian Diagnostics. Being part of Gradian Diagnostics allows us to accelerate growth and develop new innovative solutions that help hospitals and labs with the challenges and opportunities they face today and in the future in routine microbial pathogen diagnostics and molecular microbiology research.
Our highly experienced team of researchers, technicians and diagnostic specialists in addition to our businesses and services will remain unchanged. Our customers, distributors and partners can continue to rely on our high quality solutions and our excellent support. The offices and production site will remain in Bremen, Germany.
Gradian Diagnostics is a holding company based in Miami, USA, working on expanding diagnostic solutions by acquiring assets and companies with validated products around the world. Please follow the link for the official press release.